BioSpace News Archive

− Product and Pipeline Goals Include Execution on Four Commercial Brands, One New NDA Filing, Two Phase 3 Data Readouts, Amongst Other Milestones – – New Clinical Data Presented from Phase 1 Monotherapy Study of ALN-AGT Show Mean Reduction in 24-Hour Systolic Blood Pressure of Over 15 mm Hg – – New Highlighted Programs Include Investigational RNAi Therapeutics for Recurrent Renal Stones, Non-alcoholic Steatohepatitis (NASH),

- EmendoBio to operate as an independent subsidiary of AnGes with full access to AnGes’ global development resources to accelerate development and manufacturing capabilities for EmendoBio’s dual OMNI™ genome editing technology platforms - Acquisition significantly expands AnGes’ global leadership, broad capabilities in genetic medicine as well as its pipeline and platforms NEW YORK & TEL AVIV, Israel & OSAKA, Japan--( BUSINESS WIRE )--

Karamedica, Inc. recently received a $2.5 million Small Business Innovative Research (SBIR) Phase II grant from the National Institute on Aging to continue developing a microparticle therapy for treating cerebral amyloid angiopathy (CAA), a condition responsible for inflicting significant neurologic damage and afflicting greater than 85% of Alzheimer’s patients. The grant builds on Karamedica’s nose-to-brain delivery system that was validated

TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today that Michel Thérin has been appointed to the Company’s Board of Directors.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort of the Company’s Phase 2 REDUX chronic kidney disease (CKD) study.

Xentria, Inc., a biopharmaceutical company focused on developing novel biologics and biosimilars to address unmet clinical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its intravenous TNF-α inhibitor, XTMAB-16, for the treatment of sarcoidosis.

Brain Scientific Inc . (OTCQB: BRSF ), a neurology-focused medical device and software company, today announced it has launched a Regulation A+ equity crowdfunding campaign following the qualification of its Form 1-A offering circular by the U.S. Securities and Exchange Commission. The purpose of this offering is to allow both accredited and non-accredited potential investors the opportunity to help the Company further the pen

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced the dosing of the first patient in its Phase 2a clinical trial of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) for the treatment of hospitalized patients with COVID-19.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to report, in a descriptive format, positive trending interim data for the Phase 2b part of the Company’s Phase 2b/3 clinical study of Ifenprodil for COVID-19.

Cerus Corporation (Nasdaq: CERS) today announced that its distribution partner, Companhia Energética Integrada (CEI), was awarded a three-year contract with the HemoMinas Foundation (“HemoMinas”) of Brazil for the INTERCEPT Blood System for platelets. HemoMinas provides services and blood products in the state of Minas Gerais, and the Hemocentro of Belo Horizonte – the largest blood service of HemoMinas – distributes app